Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of California San Diego - Moores Cancer Center
La Jolla, California, United States
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, United States
- Columbia University Irving Medical Center
New York, New York, United States
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
- University of Cincinnati
Cincinnati, Ohio, United States
- Penn Medicine Abramson Cancer Center
Philadelphia, Pennsylvania, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 1 Feb 2023
- Primary completion
- 31 Aug 2026
- Completion
- 31 Dec 2026
- Last update posted
- 10 Jul 2026
- Registered enrollment
- 32
- Registry id
- NCT05498272
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.